Persistence of disease flares is associated with an inadequate colchicine dose in familial Mediterranean fever: A national multicenter longitudinal study
- Autori: Bustaffa M.; Mazza F.; Sutera D.; Carrabba M.D.; Alessio M.; Cantarini L.; Obici L.; Rigante D.; Maggio M.C.; Insalaco A.; Simonini G.; Cattalini M.; Conti G.; Olivieri A.N.; Barone P.; Miniaci A.; Moressa V.; Magnolia M.G.; Breda L.; Montin D.; Spagnolo A.; Fabio G.; Orlando F.; Gaggiano C.; Mussinelli R.; Capozio G.; Celani C.; Marrani E.; Ricci F.; Calzatini F.; Lancieri M.; Ruperto N.; Gattorno M.; Gallizzi R.
- Anno di pubblicazione: 2021
- Tipologia: Articolo in rivista
- OA Link: http://hdl.handle.net/10447/593373
Abstract
Familial Mediterranean fever (FMF) is characterized by self limited episodes of fever and polyserositis.1 MEFV gene en codes for a protein named Pyrin, which plays a pivotal role in the activation and secretion of IL-1.2 Daily colchicine is highly effective in preventing attacks in this disorder in a dose-related fashion.3 Many definitions of colchicine resistance are available in the literature. The European League Against Rheumatism (EULAR) guidelines defined resistance as one or more attacks per month in compliant patients who had been receiving the maxi mally tolerated dose for at least 6 months.4 A similar definition was confirmed by a recent consensus among experts.5 In the present national multicentric longitudinal study, we analyze the impact of colchicine treatment on disease activity and quality of life in real life in pediatric and adult patients with FMF.